Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Melanoma 69Carcinoma, Non-Small-Cell Lung 41Carcinoma, Renal Cell 38Neoplasm Metastasis 22Carcinoma, Hepatocellular 15Neoplasms 14Colorectal Neoplasms 13Brain Neoplasms 13Skin Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 10Lung Neoplasms 10Kidney Neoplasms 10Uveal Melanoma 9Ovarian Neoplasms 9Urinary Bladder Neoplasms 8Sarcoma 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Mesothelioma 7Glioblastoma 7Clear-cell metastatic renal cell carcinoma 7Carcinoma, Merkel Cell 7Recurrence 6Myelodysplastic Syndromes 6Colonic Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Multiple Myeloma 5Mesothelioma, Malignant 5

Interventions

Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Biopsy 3Fluorouracil 2Etoposide 2Cyclophosphamide 2liposomal doxorubicin 1fludarabine 1dehydroftorafur 1carmustine, poliferprosan 20 drug combination 1cabozantinib 1axicabtagene ciloleucel 1Zidovudine 1X-Rays 1Vincristine 1Valganciclovir 1Triage 1Therapeutics 1Standard of Care 1Sodium Chloride 1Smoking Devices 1Sirolimus 1Sigmoidoscopy 1Sentinel Lymph Node Biopsy 1Rituximab 1Restraint, Physical 1Raltegravir Potassium 1Radiotherapy, Intensity-Modulated 1Proctoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HIV Infections × Ipilimumab × 1 year × Clear all
NCT02408861 2026-01-21

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
79 enrolled 24 charts
GastrointestinalSarcomaThoracic

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡